Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
Questions to Be Answered for ctDNA Biomarkers, Targeted Therapy in UC
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
October 1, 2024
At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers.
View More
EGFR Inhibition in Advanced UC
Vadim Koshkin, MD
Advanced Urothelial Carcinoma
|
September 23, 2024
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
View More
Pre-Treatment Risk Factors for EV-Induced Peripheral Neuropathy in aUC: Analysis of the UNITE Study
Amanda Nizam, MD
Advanced Urothelial Carcinoma
|
September 23, 2024
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
View More
Investigating Relationship Between QOL, Perception of Cure in Metastatic Disease
Jordana Jampel
Advanced Renal Cell Carcinoma
|
September 30, 2024
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Read More
Disitamab Vedotin Plus Pembrolizumab in aUC: HER2 Status, Safety and Efficacy Data
Matthew Galsky, MD
Advanced Urothelial Carcinoma
|
September 18, 2024
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
View More
EV-302: Nectin-4 Expression and Response to First-Line EV/Pembro
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 13, 2024
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Read More
Futibatinib Plus Pembrolizumab for Patients With Metastatic Urothelial Carcinoma
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 12, 2024
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Read More
Promising Early Results for Disitamab Vedotin and Pembrolizumab Combo in HER2-Positive Urothelial Cancer
Brandon Twyford
Advanced Urothelial Carcinoma
|
September 12, 2024
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Read More
Novel Antibody-Drug Conjugate Shows Promise for Pretreated UC
Jordana Jampel
Advanced Urothelial Carcinoma
|
September 10, 2024
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Read More
Consistent PFS, OS Benefit With Enfortumab Vedotin Plus Pembrolizumab
Jordana Jampel
Advanced Urothelial Carcinoma
|
September 10, 2024
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
Read More
TROPHY-U-01 Cohort 2 Shows Efficacy of Sacituzumab Govitecan Monotherapy for Advanced UC
Emily Menendez
Advanced Urothelial Carcinoma
|
September 5, 2024
Cohort 2 of TROPHY-U-01 showed that sacituzumab govitecan monotherapy can benefit cisplatin-ineligible patients.
Read More
Perioperative Therapy, ctDNA for Advanced Bladder Cancer
Guru P. Sonpavde, MD
Advanced Urothelial Carcinoma
|
August 12, 2024
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
View More
EVITA Criteria: Opening Doors for Novel Therapies in EV/Pembro-Ineligible Patients
Enrique Grande, MD, PhD, MSc
Advanced Urothelial Carcinoma
|
July 30, 2024
Drs. Grande, Nizam continue their conversation on EVITA, including the personalization of treatment to predict toxicity.
View More
EVITA Criteria to Identify Patients Unfit for EV/Pembro
Enrique Grande, MD, PhD, MSc
Advanced Urothelial Carcinoma
|
July 30, 2024
Drs. Grande and Nizam discuss the development of criteria for identifying mUC patients ineligible for EV/pembro.
View More
EV-302 Patient-Reported Outcomes
Shilpa Gupta, MD
Advanced Urothelial Carcinoma
|
July 16, 2024
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
View More
How Does Organ-Specific Tumor Response to EV Affect Patients With Metastatic UC?
Katy Marshall
Advanced Urothelial Carcinoma
|
July 8, 2024
The recorded ORR was 53.5%, and the disease control rate was 74.1%.
Read More
NECTIN4 Amplification Predicts Response to EV in Metastatic Urothelial Carcinoma
Niklas Klümper, MD
Advanced Urothelial Carcinoma
|
June 21, 2024
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
View More
JAVELIN Bladder 100 Long-Term Data: Patients With Histological Subtypes, Low Tumor Burden
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
June 12, 2024
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
View More
Bladder Cancer Roundup: Enfortumab Vedotin, Nivolumab, and More
Petros Grivas, MD, PhD
Advanced Urothelial Carcinoma
|
June 12, 2024
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
View More
Cisplatin-Eligible, -Ineligible Population Analysis From EV-302
Michiel van der Heijden, MD, PhD
Advanced Urothelial Carcinoma
|
June 6, 2024
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
View More
Load More
Advertisement
Advertisement
Advertisement